Dr Diana Barrett Wiseman, MD | |
325 9th Ave, Seattle, WA 98104-2420 | |
(206) 744-3000 | |
Not Available |
Full Name | Dr Diana Barrett Wiseman |
---|---|
Gender | Female |
Speciality | Neurosurgery |
Experience | 30 Years |
Location | 325 9th Ave, Seattle, Washington |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1932167368 | NPI | - | NPPES |
1932167368 | Medicaid | WA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207T00000X | Neurological Surgery | MD00040160 (Washington) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Harborview Medical Center | Seattle, WA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
The Association Of University Physicians | 0446162697 | 3009 |
News Archive
A new 5-minute test to identify elderly patients with dementia promises to give doctors a more sensitive tool to use in the Annual Wellness Examination. The Memory Orientation Screening Test (MOST™) developed by Mitchell Clionsky, Ph.D., a neuropsychologist, and Emilymarie Clionsky, MD, an internist/psychiatrist, is based on their clinical experience with thousands of patients who suffer from Alzheimer's Disease and other dementias, which now afflicts more than 5 million Americans.
Biocompatible gold nanoparticles designed to convert near-infrared light to heat have been shown to safely and effectively ablate low- to intermediate-grade tumors within the prostate, according to a study conducted at the Icahn School of Medicine and published in the journal Proceedings of the National Academy of Sciences.
Millennium: The Takeda Oncology Company today announced the initiation of a Phase II clinical trial examining rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without VELCADE® (bortezomib) for Injection for patients with a common type of lymphoma. The study will examine previously untreated patients with a genomically defined subtype of lymphoma called non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma.
Unequal exposure to environmental pollutants acting as endocrine-disrupting chemicals is an under-recognized risk factor that may play a key role in driving the higher rates of diabetes among minority and low-income populations, according to a new article in the journal Diabetes Care.
› Verified 5 days ago
Entity Name | The Association Of University Physicians |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1023041159 PECOS PAC ID: 0446162697 Enrollment ID: O20031105000244 |
News Archive
A new 5-minute test to identify elderly patients with dementia promises to give doctors a more sensitive tool to use in the Annual Wellness Examination. The Memory Orientation Screening Test (MOST™) developed by Mitchell Clionsky, Ph.D., a neuropsychologist, and Emilymarie Clionsky, MD, an internist/psychiatrist, is based on their clinical experience with thousands of patients who suffer from Alzheimer's Disease and other dementias, which now afflicts more than 5 million Americans.
Biocompatible gold nanoparticles designed to convert near-infrared light to heat have been shown to safely and effectively ablate low- to intermediate-grade tumors within the prostate, according to a study conducted at the Icahn School of Medicine and published in the journal Proceedings of the National Academy of Sciences.
Millennium: The Takeda Oncology Company today announced the initiation of a Phase II clinical trial examining rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without VELCADE® (bortezomib) for Injection for patients with a common type of lymphoma. The study will examine previously untreated patients with a genomically defined subtype of lymphoma called non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma.
Unequal exposure to environmental pollutants acting as endocrine-disrupting chemicals is an under-recognized risk factor that may play a key role in driving the higher rates of diabetes among minority and low-income populations, according to a new article in the journal Diabetes Care.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Diana Barrett Wiseman, MD Po Box 50095, Seattle, WA 98145-5095 Ph: (206) 520-5700 | Dr Diana Barrett Wiseman, MD 325 9th Ave, Seattle, WA 98104-2420 Ph: (206) 744-3000 |
News Archive
A new 5-minute test to identify elderly patients with dementia promises to give doctors a more sensitive tool to use in the Annual Wellness Examination. The Memory Orientation Screening Test (MOST™) developed by Mitchell Clionsky, Ph.D., a neuropsychologist, and Emilymarie Clionsky, MD, an internist/psychiatrist, is based on their clinical experience with thousands of patients who suffer from Alzheimer's Disease and other dementias, which now afflicts more than 5 million Americans.
Biocompatible gold nanoparticles designed to convert near-infrared light to heat have been shown to safely and effectively ablate low- to intermediate-grade tumors within the prostate, according to a study conducted at the Icahn School of Medicine and published in the journal Proceedings of the National Academy of Sciences.
Millennium: The Takeda Oncology Company today announced the initiation of a Phase II clinical trial examining rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without VELCADE® (bortezomib) for Injection for patients with a common type of lymphoma. The study will examine previously untreated patients with a genomically defined subtype of lymphoma called non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma.
Unequal exposure to environmental pollutants acting as endocrine-disrupting chemicals is an under-recognized risk factor that may play a key role in driving the higher rates of diabetes among minority and low-income populations, according to a new article in the journal Diabetes Care.
› Verified 5 days ago
George A Ojemann, Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: University Of Washington Medical Ctr, 1959 Ne Pacific St, Seattle, WA 98195 Phone: 206-598-5637 | |
Mr. Trent Lane Tredway, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 737 Olive Way Apt 2502, Seattle, WA 98101 Phone: 206-623-1334 Fax: 206-623-1677 | |
Daniel A Lazar, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1560 N 115th St, 209, Seattle, WA 98133 Phone: 206-368-1701 Fax: 206-363-0019 | |
Mohammed Basamh, Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 550 17th Ave Ste 500, Seattle, WA 98122 Phone: 206-320-2451 | |
Dr. Christoph Paul Hofstetter, M.D., PH.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1959 Ne Pacific St, Campus Box 356470, Room Rr734, Seattle, WA 98195 Phone: 507-202-9523 | |
David Keisho Su, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 900 Lenora St, 501, Seattle, WA 98121 Phone: 559-260-0047 | |
Syed Shabaz Azeem, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 125 16th Ave E, Seattle, WA 98112 Phone: 206-326-3000 |